Depression, Drive
Conditions
Brief summary
This project will assess how depression, preclinical AD, and antidepressants affect driving behavior in cognitively normal older adults (65 years).
Detailed description
The long-term goal is to accurately identify who is at risk of decline in driving, to forecast when decline will occur, and to intervene before decline, thereby reducing the numbers of crashes, injuries, and death in older adults. The findings indicate that the long preclinical stage of Alzheimer disease (AD), as reflected in amyloid imaging and cerebrospinal fluid (CSF) biomarkers among cognitively normal participants, is associated with poorer driving performance on a standardized road test. This project will assess how depression, preclinical AD, and antidepressants affect driving behavior in cognitively normal older adults (65 years).
Interventions
A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
Sponsors
Washington University School of Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Inclusion criteria
* Drive on average at least once per week * Has a valid driver's license * Willing to complete blood draw * Willing to complete either lumbar puncture or PET imaging * 65 years or older * Speaks English
Exclusion criteria
* Not willing to complete blood draw and/or one other biomarker * Less than 65 years of age * Does not drive a vehicle/ is no longer actively driving
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Latitude via DRIVES chip | Daily for up to five years | The latitude coordinate of the location of the vehicle being driven |
| Longitude via DRIVES chip | Daily for up to five years | The Longitude coordinate of the location of the vehicle being driven |
| Vehicle Speed via DRIVES chip | Daily for up to five years | The speed at which the vehicle being driven is moving. |
| Speed Limit via DRIVES chip | Daily for up to five years | The posted speed limit for the location that participant is driving. |
| Difference via DRIVES chip | Daily for up to five years | The difference between the speed at which the vehicle is moving and the posted speed limit for the location. |
| Event Name via DRIVES Chip | Daily for up to five years | Name of the geofence in which participant had a driving event. |
| Address via DRIVES chip | Daily for up to five years | Address of the location in which participant had a driving event. |
| Event Type via DRIVES chip | Daily for up to five years | Enumeration describing the type of event: ignition on, heartbeat, ignition off, braking, acceleration, overspeeding, idling, low fuel, cornering, low battery event, diagnostic event triggered. |
| Event Time via DRIVES chip | Daily for up to five years | Timestamp in GMT on which the event occurred. |
| Odometer Reading via DRIVES chip | Daily for up to five years | Odometer reading of the vehicle. |
| Trip Distance via DRIVES chip | Daily for up to five years | Total distance covered during the trip |
| Peak Speed via DRIVES chip | Daily for up to five years | Highest speed attained by the vehicle during the trip. |
| Average Speed | Daily for up to five years | Average trip speed of the vehicle. |
| Initial Speed via DRIVES chip | Daily for up to five years | Speed at the beginning of the trip. |
| Final Speed via DRIVES chip. | Daily for up to five years | Speed at the end of the trip. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Trail Making A | Annually for up to five years | This will be tested annually in a private office setting using paper and pen assessments. This will test executive function. |
| Trail Making B | Annually for up to five years | This will be tested annually in a private office setting using paper and pen assessments. This will test executive function. |
| Montreal Cognitive Assessment (MoCA) Total | Annually for up to five years | This will be tested annually in a private office setting using paper and pen assessments. This will screen for cognitive impairment. |
| Category Fluency | Annually for up to five years | This will be tested annually in a private office setting using paper and pen assessments. This will test language ability. |
| Phonemic Fluency | Annually for up to five years | This will be tested annually in a private office setting using paper and pen assessments. This will test language ability. |
| Mini Mental Status Exam | Annually for up to five years | This will be tested annually in a private office setting using paper and pen assessments. This will screen for cognitive impairment. |
| Clinical Dementia Rating (CDR) Sum of Boxes | Annually for up to five years | This will be tested annually in a private office setting using paper and pen assessments. This will test for cognitive impairment/dementia severity. |
Countries
United States
Contacts
CONTACTKaylin Taylor, MA
CONTACTBeau Ances, MD, PhD
PRINCIPAL_INVESTIGATORBeau Ances, MD, PhD
Washington University School of Medicine
Outcome results
None listed